Guggenheim Capital LLC Increased Stake in Abbvie INC (ABBV)

Adjust Comment Print

$157,458 worth of AbbVie Inc. The Livingston Group Asset Management Southport Capital Management holds 500 shares with $48,000 value, down from 12,996 last quarter.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The overall volume in the last trading session was 6,402,961 shares. ABBV has also 6.40M shares volume. (NYSE:ABBV) for 183,696 shares. ABBV outperformed by 27.65% the S&P500.

Fairfield Bush & Company decreased Qualcomm Inc. Fairfield Bush & Company sold 8,815 shares as Qualcomm Inc. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 1.00% with $1.58 Billion sitting short, betting on future declines. The stock decreased 1.65% or $0.25 during the last trading session, reaching $14.9. About 4.63 million shares traded. Stantec Inc. (STN) has declined 6.02% since April 13, 2017 and is downtrending. It has underperformed by 25.58% the S&P500. Its up 0.06, from 1.3 in 2017Q3.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Mendel Money Mngmt owns 10,751 shares. (NYSE:ABBV). Dekabank Deutsche Girozentrale reported 0.22% of its portfolio in AbbVie Inc. (NYSE:ABBV). Hm Payson & invested in 340,570 shs or 1.32% of the stock. Wms Prns Ltd Liability holds 0.11% or 9,707 shares in its portfolio. Sector Pension Invest Board reported 85,435 shares or 0.05% of all its holdings. Peavine Cap Ltd holds 21,600 shares. Tctc Ltd Limited Liability Company reported 0.81% of its capital in AbbVie Inc. Nj State Employees Deferred Compensation Plan accumulated 40,000 shares or 0.67% of the stock.

COPYRIGHT VIOLATION NOTICE: "ZWJ Investment Counsel Inc". Citigroup Inc. restated a "buy" rating on shares of AbbVie in a research report on Tuesday, November 8th. Therefore 42% are positive. BMO Capital Markets lowered shares of AbbVie from a "market perform" rating to an "underperform" rating and cut their price target for the stock from $125.86 to $84.00 in a report on Monday, January 29th. The stock now has a consensus rating of "Buy" and an average price target of $117.85. On Monday, October 16 the stock of AbbVie Inc. (NYSE:ABBV) earned "Hold" rating by BMO Capital Markets on Friday, April 28. Bronfman E.L. Rothschild L.P. now owns 26,248 shares of the company's stock valued at $1,903,000 after buying an additional 3,706 shares during the period. Jennison Associates LLC purchased a new position in AbbVie during the 3rd quarter worth approximately $544,418,000. (NYSE:ABBV). Private Capital holds 1.22% or 36,310 shares. The firm has "Underweight" rating given on Friday, March 16 by JP Morgan. Finally, Jefferies Group boosted their target price on AbbVie from $115.00 to $120.00 and gave the stock a "buy" rating in a report on Thursday, January 4th. Finally, Capital International Investors grew its stake in shares of AbbVie by 137.7% in the 3rd quarter. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. The rating was maintained by Leerink Swann on Tuesday, December 5 with "Buy". On Friday, October 13 the company was maintained by UBS. The rating was downgraded by Suntrust Robinson on Thursday, December 22 to "Hold". During the same period in the previous year, the company posted $1.20 earnings per share. sell-side analysts anticipate that AbbVie will post 7.51 EPS for the current fiscal year. The company reported $1.48 EPS for the quarter, topping the Zacks' consensus estimate of $1.44 by $0.04.

New England Research & Management Inc increased United Technologies (NYSE:UTX) stake by 2,400 shares to 9,748 valued at $1.24 million in 2017Q4. Starbucks (NASDAQ:SBUX) was raised too.

Since October 30, 2017, it had 0 insider buys, and 12 insider sales for $49.35 million activity.

Earnings per Share Details of AbbVie Inc.: The EPS of ABBV is strolling at 5.54, measuring its EPS growth this year at 52.6 percent. 18,129 shares were sold by RICHMOND TIMOTHY J., worth $2.15M. $2.15M worth of AbbVie Inc. The total amount of shares outstanding is 196.14M, giving the company a market capitalization of about 8.05B. On Wednesday, February 28 SEVERINO MICHAEL sold $311,684 worth of AbbVie Inc. (NYSE:ABBV) or 83,574 shs on Wednesday, February 28.

Investors sentiment decreased to 0.83 in Q4 2017. Its down 0.05, from 0.85 in 2017Q3. 52 funds opened positions while 124 raised stakes. 4,000 were reported by Bamco Inc New York. Axa owns 2.99M shares for 0.75% of their portfolio. Jarislowsky Fraser accumulated 259,727 shares. Choate Invest invested in 0.52% or 104,854 shares. Kbc Nv owns 951,965 shares for 0.79% of their portfolio. Evermay Wealth Mgmt Lc invested in 11,991 shares or 0.42% of the stock. Leuthold Group Llc who had been investing in Abbvie Inc. for a number of months, seems to be bullish on the $145.71B market cap company. 41,400 were accumulated by Independent. Hemenway Tru Com Ltd Com reported 30,636 shares. Van Cleef Asset Managementinc owns 8,400 shares. Fmr Llc holds 14.90M shares. Atlanta Management L L C reported 0.69% of its portfolio in RPM International Inc.

Analysts await Dominion Energy Midstream Partners, LP (NYSE:DM) to report earnings on May, 3. They expect $0.35 earnings per share, up 16.67% or $0.05 from last year's $0.3 per share. Corporate insiders own 0.07% of the company's stock. EPS is an indicator of company profit because the more earnings a company can generate per share, the more valuable each share is to investors. Another trade for 663 shares valued at $37,519 was sold by ROGERS ALEXANDER H. Also, insider Laura J. Schumacher sold 25,000 shares of the business's stock in a transaction dated Thursday, March 1st. The company has Beta Value of 1.59 and ATR value of 3.69.